Wilkinson DI - Search Results

1

The parasitic worm product ES-62 protects the osteoimmunology axis in a mouse model of obesity-accelerated ageing.

Harnett MM, Doonan J, Lumb FE, Crowe J, Damink RO, Buitrago G, Duncombe-Moore J, Wilkinson DI, Suckling CJ, Selman C, Harnett W. Harnett MM, et al. Among authors: wilkinson di. Front Immunol. 2022 Aug 29;13:953053. doi: 10.3389/fimmu.2022.953053. eCollection 2022. Front Immunol. 2022. PMID: 36105811 Free PMC article.

2

Signal peptide mutations in RANK prevent downstream activation of NF-κB.

Crockett JC, Mellis DJ, Shennan KI, Duthie A, Greenhorn J, Wilkinson DI, Ralston SH, Helfrich MH, Rogers MJ. Crockett JC, et al. Among authors: wilkinson di. J Bone Miner Res. 2011 Aug;26(8):1926-38. doi: 10.1002/jbmr.399. J Bone Miner Res. 2011. PMID: 21472776 Free PMC article.

3

Experimental studies on topoisomerase inhibitor camptothecin as an antipsoriatic agent.

Lin X, Wilkinson DI, Huang T, Farber EM. Lin X, et al. Among authors: wilkinson di. Chin Med J (Engl). 1999 Jun;112(6):504-8. Chin Med J (Engl). 1999. PMID: 11601327

4

Camptothecin induces differentiation, tissue transglutaminase and apoptosis in cultured keratinocytes.

Lin XR, Wilkinson DI, Farber EM. Lin XR, et al. Among authors: wilkinson di. Exp Dermatol. 1998 Aug;7(4):179-83. doi: 10.1111/j.1600-0625.1998.tb00321.x. Exp Dermatol. 1998. PMID: 9758415

5

Persistence of T-cell clones in psoriatic lesions.

Chang JC, Smith LR, Froning KJ, Kurland HH, Schwabe BJ, Blumeyer KK, Karasek MA, Wilkinson DI, Farber EM, Carlo DJ, Brostoff SW. Chang JC, et al. Among authors: wilkinson di. Arch Dermatol. 1997 Jun;133(6):703-8. Arch Dermatol. 1997. PMID: 9197823

6

Report of the Ad Hoc Committee on the Oklahoma Health Care Authority and SoonerCare.

McCaffree MA, Tisdal RG, Storms BL, Dewberry GB, Wilkinson DI, Thomason JM, Rowland H, Thomason JM. McCaffree MA, et al. Among authors: wilkinson di. J Okla State Med Assoc. 1997 May-Jun;90(5):195-203. J Okla State Med Assoc. 1997. PMID: 9203769 No abstract available.

7

CD8+ T-cells in psoriatic lesions preferentially use T-cell receptors V beta 3 and/or V beta 13.1 genes.

Chang JC, Smith LR, Froning KJ, Schwabe BJ, Laxer JA, Caralli LL, Kurkland HH, Karasek MA, Wilkinson DI, Carlo DJ, et al. Chang JC, et al. Among authors: wilkinson di. Ann N Y Acad Sci. 1995 Jul 7;756:370-81. doi: 10.1111/j.1749-6632.1995.tb44541.x. Ann N Y Acad Sci. 1995. PMID: 7645853

8

Clinical testing of new drugs for lesional skin diseases such as psoriasis A new delivery system.

Farber EM, Wilkinson DI, Trozak DJ. Farber EM, et al. Among authors: wilkinson di. Skin Res Technol. 1995 Feb;1(1):41-3. doi: 10.1111/j.1600-0846.1995.tb00013.x. Skin Res Technol. 1995. PMID: 27328221

9

Phospholipase A2 activity of peripheral-blood mononuclear leukocytes in psoriasis.

Leder RO, Vossough S, Weltman H, Wilkinson DI. Leder RO, et al. Among authors: wilkinson di. Dermatology. 1995;190(4):318-9. doi: 10.1159/000246727. Dermatology. 1995. PMID: 7655114 Free article. No abstract available.

10

Nerve growth factor increases the mitogenicity of certain growth factors for cultured human keratinocytes: a comparison with epidermal growth factor.

Wilkinson DI, Theeuwes MJ, Farber EM. Wilkinson DI, et al. Exp Dermatol. 1994 Oct;3(5):239-45. doi: 10.1111/j.1600-0625.1994.tb00283.x. Exp Dermatol. 1994. PMID: 7881770

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

48 results

Search Page